It is possible that a better understanding of the ability of GNAQQ209L to switch from acting as an oncogene to an inhibitor of melanocyte growth could lead to new therapies for GNAQ and GNA11 mutant melanomas, which lack effective treatment options for metastatic disease. The gene discussed is GNA11; the disease is metastatic neoplasm.